One strategy for the use of neural stem cells (NSCs) in treating neurological disorders is as transplantable "biological minipumps", in which genetically engineered neural stem cells serve as sources of secreted therapeutic (neuroprotective or tumoricidal) agents. Neural stem cells are highly mobile within the brain and demonstrate a tropism for various types of central nervous system (CNS) pathology, making them promising candidates for targeted gene delivery vehicles. Although neural stem cells have also been proposed as a potential source of replacement neurons and astrocytes to repopulate injured or degenerating neural circuits, the challenges involved in rebuilding damaged brain architecture are substantial and remain an active area of investigation. In contrast, the use of NSCs as biological minpumps does not rely on neuronal differentiation, axonal targeting, or synaptogenesis. This strategy may be a faster route to cell-based therapy of the CNS and is poised to move into human clinical trials. This review considers two types of neurologic disease that may be suitable targets for this alternative approach to NSC therapy: glial brain tumors and traumatic brain injury. We examine some of the key scientific and technical issues that must be addressed for the successful use of NSCs as minipumps.
INTRODUCTION
differentiation of NSCs into neurons or astrocytes, axonal targeting and synaptogenesis are not required for a therapeutic effect; 3) the therapeutic effect of an individual stem cell is expanded because it secretes the therapeutic agent for uptake by neighboring cells; 4) the propensity of neural stem cells to migrate can be exploited to deliver the therapeutic agent throughout the brain to where it is needed, but the degree and direction of migration are dependent on whether the pathology is focal or global, among other factors; 5) there is an essential need to ensure that CNS transplants are stable and do not transform into tumors; and 6) the disease state dictates the need for long-term and/or regulated gene expression.
Despite intense medical, surgical, and pharmacological efforts to minimize the impact of central nervous system (CNS) injury and disease, the inability of the brain to fully repair itself often leads to permanent neurological deficits. This problem has motivated the search for therapeutic strategies for the restoration of CNS function. Much attention has been focused on the ability of neural stem cells to differentiate into neurons, astrocytes, and oligodendrocytes that can potentially replace damaged neural circuits. However, there are numerous scientific and technical obstacles that remain to be overcome before cell replacement therapy could be a viable strategy for brain repair in humans. An alternative application of neural stem cells (NSCs) that has emerged in recent years is their use as "biological minipumps" for therapeutic or neuroprotective factors, a strategy that may be more quickly translated into the clinical arena.
With regard to point #6, several studies have demonstrated that NSCs engineered with foreign genes can express them stably after being transplanted into in vivo settings [2] [3] [4] . The use of constitutively active "housekeeping" promoters, the use of insulators, and the integration of the transcription unit into open chromatin have been important factors for achieving long-term gene expression without transcriptional downregulation. For genetically engineered cells, specific issues that must be addressed before clinical use include: the risk of insertional mutagenesis by integrating (lentiviral or retroviral) vectors, the persistence of expression from episomal vectors such as AAV, the need to ensure that transplanted cells do not produce any replication-competent virus, the possibility of transcriptional silencing of the transgene, and good manufacturing practice (GMP) production of a uniformly transduced cell population for clinical trials. However, the first clinical trial of neural stem cells for brain transplantation will likely be performed with unengineered cells. A proprietary line of fetal human neural progenitor cells (HuCNS-SC(TM)) was recently approved by the FDA and a phase I trial was announced at Oregon Health and Science University in March 2006. These cells, which Much of the groundbreaking work on this application of neural stem cells has been conducted in animal models of human lysosomal storage diseases, most of which have some degree of neurological dysfunction that must be treated by early, widespread, and lifelong delivery of the therapeutic agent directly to the brain (reviewed in ref. [1] ). In general, several key points have emerged from these studies: 1) Peripheral delivery of CNS therapeutic agents is usually ineffective due to the lack of trafficking across the bloodbrain barrier (BBB), and the delivery of growth factors via this route may even be harmful, highlighting the need for therapeutic agents to be delivered directly to the CNS; 2) express endogenous levels of palmitoyl-protein thioesterase 1 and tripeptidyl peptidase I, are planned for CNS transplantation in children with neuronal ceroid lipofuscinosis (Batten's disease) [5] .
animal models [9, 18] . Moreover, these authors found that NSCs engineered to express cytosine deaminase [9] Multiple studies in the past five years examining different rodent models, anti-tumor agents, and sources of NSCs have supported the feasibility of cell-based gene therapy of brain tumors (reviewed in ref. [20] ). Other types of progenitor cells, including bone marrow-derived stem cells [21] , mesenchymal stem cells [22, 23] , hematopoietic stem cells [24] , and endothelial progenitors [25] , have also been identified as viable means of delivering genes to intracranial tumors in animal models (summarized in Table  1 ). Despite this rapid progress, many questions remain unanswered. The full potential of cell-based brain tumor gene therapy will not be realized before these issues, described below, are more thoroughly explored. In this review, we discuss two disorders of the CNS, brain tumors and traumatic brain injury, that may benefit from targeted NSC-based gene delivery in different ways. Specifically, NSCs could be tailored to deliver toxic antitumor agents in the case of brain tumors or trophic factors capable of supporting brain repair in the case of traumatic brain injury. We will use these disease states as case studies to point out some important unresolved scientific and technical issues and to weigh the benefits against the risks of this promising therapeutic modality.
Potential Tumorigenicity of Neural Stem Cells
The relationship between NSCs and brain tumors is currently a matter of great debate, and it is unclear whether unaltered NSCs facilitate or hinder tumor growth and development. A growing literature suggests that NSCs, as opposed to dedifferentiated mature brain cells, are the precursors for various types of brain tumors. Several researchers have isolated so-called brain tumor stem cells (BTSCs) from human tumors. These sub-populations of cells express CD133, as well as the NSC markers nestin and musashi-1, and can be continually propagated to create new tumor clones in vitro and in vivo [26] [27] [28] [29] [30] . The subventricular zone has emerged as a leading candidate for the source of BTSCs [31, 32] . However, the specific molecular aberrations that distinguish BTSCs from non-tumorigenic NSCs are not well defined (reviewed in ref. [33] ). Because multiple mutations, each of which is an independent, stochastic event, are required for the cancerous transformation of normal somatic cells, it appears unlikely that a population of non-tumorigenic NSCs transplanted into the brain would contribute to an oncogenic process. There are a few caveats to this supposition. Since there is currently no technical means of identifying potential BTSCs within a population of non-tumorigenic NSCs, one cannot be sure that a population of stem cells intended for transplantation is completely free of rare BTSCs. An additional concern is whether the tumor environment and/or concurrent chemotherapy would selectively drive NSC transformation into tumors. Experimentally, there has been evidence of teratoma formation after the transplantation of embryonic stem cells [34] [35] [36] , but we are unaware of any reports of transplanted NSCs converting to tumor cells or assisting the growth of an established tumor. Much more research is clearly needed to ascertain the conditions that promote the neoplastic transformation of stem cells, in addition to the molecular pathways involved. For any potential human trials with NSCs, it would be prudent to include a "kill switch" in
GLIOBLASTOMA MULTIFORME AND OTHER CNS TUMORS
Over 17,000 patients are diagnosed every year with primary malignant brain tumors [14] . Despite years of research and many technical refinements, current therapies for gliomas, especially glioblastoma multiforme (GBM), continue to disappoint in their outcomes [15] . The median survival for patients with GBM a mere 16-18 months, a statistic that has not changed significantly in the past twenty years. One of the primary reasons that patient prognosis remains so poor is the diffuse, highly infiltrative nature of glioma cells. Although surgical resection can remove the bulk of most tumors, there is at present no means of effectively eradicating the microscopic pockets of tumor cells that are inevitably left behind. These residual, highly migratory glioma microsatellites are responsible for the tumor recurrences that lead to mortality and represent a significant barrier to successful glioma therapies.
Within the last decade, a potential solution to the problem of glioma infiltration has emerged in the form of neural stem cells. Studies from the late 1990's documented the extraordinary capacity of transplanted NSCs to migrate within the central nervous system, especially towards areas of pathology, and demonstrated that NSCs could be engineered to express foreign genes [2, 3, 16, 17] . In 2000, two groups extended these findings to the field of brain tumor research, providing evidence that transplanted NSCs exhibited a tropism for glioma cells in vitro and in vivo in the genetic engineering strategy, as a means of destroying the stem cells if they were to malfunction in any way.
that this anti-tumor activity was both NSC-and gliomaspecific, because other stem cell lines failed to inhibit glioma growth and because some glioma lines proliferated regardless of the presence of ST14A or HiB5 cells. Other studies using primary NSC cultures have reported conflicting results, supporting an intrinsic anti-tumor activity in some cases [38] but not in others [39, 40] . Two potential mechanisms for NSC control of tumor growth were suggested by a study in which co-culturing NSCs with tumor cells both inhibited tumor cell division and increased tumor cell apoptosis [41] . Future studies will need to confirm the existence of this intrinsic anti-tumor activity and, if confirmed, to identify the specific pathways and factors involved.
Intrinsic Anti-Tumor Effect of NSCs
Conversely, some published experimental evidence indicates that NSCs possess an intrinsic anti-tumor activity. Benedetti et al. observed that co-implanting NSCs with C6 glioma cells or injecting NSCs into established tumors in mice led to significantly improved survival compared to mice with gliomas alone [18] . These findings were extended by Staflin et al. who demonstrated that two NSC cell lines, ST14A and HiB5, effectively inhibited the growth of implanted N29 gliomas in vivo [37] . It appears, however,
Distribution of Migrating Neural Stem Cells
vascular endothelial growth factor (VEGF) [60] and scatter factor/hepatocyte growth factor (SF/HGF) [49] have been identified as additional regulatory factors involved in NSC chemotaxis to tumors. Stem cell factor (SCF) and the c-kit receptor have not been studied in the context of NSCs and brain tumors, but they appear to mediate the migration of endogenous NSCs towards penetrating brain injuries [61] and of hematopoietic progenitors to gliomas [24] .
In rodent models, three general paradigms have been employed to investigate NSC-based gene therapy for gliomas. Stem cells have been injected either into the tumor (at the time of tumor implantation or afterwards), into normal brain at a distance from the tumor (most often in the corpus callosum of the contralateral hemisphere), or intravenously through the animal's tail vein. In the first case, histological studies demonstrate that NSCs distribute widely throughout the tumor up to the interface of tumor and normal tissue [9, 18, 22, 23, 40, [42] [43] [44] [45] [46] . Some evidence suggests that these stem cells do not normally migrate through healthy tissue unless they are "tracking" infiltrating tumor microsatellites [9, 40, 43] . In the latter two cases, however, there appear to be two different patterns of distribution once the NSCs reach the tumor. While some studies indicate that NSCs injected at a distance from the tumor will infiltrate the tumor mass [9, 23-25, 40, 47] , others suggest that migrating stem cells surround and encapsulate the tumor without invading it [21, 48] [24] . More studies of this type will help delineate the relative importance of different factors and establish which are necessary and/or sufficient to support stem cell migration. Finally, while in vitro experiments with glioma-conditioned media strongly indicate that tumors themselves produce NSC chemoattractants [24, 47, 48, 50, 59, 60] , the possibility that the inflammatory response in the adjacent host tissue contributes to stem cell tropism is an important consideration. A chemotactic role for the host inflammatory response could explain why NSCs, attracted to the tissue at the border of tumors, sometimes encapsulate rather than infiltrate tumors. Moreover, given the propensity of NSCs to migrate toward multiple forms of brain injury, including tumors, infarcts, and trauma, inflammation may in fact serve as a common pathway for attracting stem cells.
This difference in migration pattern has important implications for therapy involving stem cell transplantation paradigms other than direct intratumoral injection. If NSCs can penetrate tumors, then tumoricidal strategies via the bystander effect or the induction of apoptosis are viable options. Such approaches would likely be less successful if NSCs encapsulate tumors but do not infiltrate them. In this case, different strategies would be required, such as using stem cells to block invasion from the main tumor mass or to help image the extent of tumor invasion for more precise surgical or radiation treatment.
Choice of Therapeutic Molecule
A number of different therapeutic molecules have been delivered to experimental gliomas via NSCs with successful results in animal models ( Table 1 ). The majority of these factors fall into three groups. In the first group are enzymes that convert pro-drugs to cytotoxic agents, specifically cytosine deaminase [9, 42, 47] and herpes simplex virus (HSV) thymidine kinase (TK) [39, 62] . The former converts 5-fluorocytosine to 5-fluorouracil, and the latter phosphorylates ganciclovir to produce nucleotide triphosphate analogs that inhibit DNA replication. Tumor cell killing is achieved through the bystander effect, which theoretically would be localized to the tumor because of stem cell migration to the tumor. In the second group are cytokines intended to stimulate an anti-tumor immune response. IL-4 and IL-12 have been studied in NSCs [18, 40, 46] while IL-2 and IFN-β have been investigated in mesenchymal stem cells [22, 23] . The third group consists of pro-apoptotic factors, in particular TNF-related apoptosisinducing ligand (TRAIL) [21, 43, 63] . This approach to tumor cell killing has the advantage of limiting inflammation that may damage normal brain tissue. Studies comparing these various options have not yet been reported.
Mechanism of Neural Stem Cell Migration Towards Pathology
Closely related to the question of NSC migration pattern is the issue of the molecular mechanism of this tropism. Because stem cells can migrate over relatively long distances towards pathology in a manner similar to leukocytes, one attractive hypothesis postulates that NSC chemotaxis to gliomas is regulated by chemokines and chemokine receptors. Stromal cell-derived factor-1 (SDF-1, also called CXCL12) and its receptor CXCR4 have been demonstrated to be involved in NSC migration towards tumors [50] , towards areas of infarction [51] , and in normal development [52] [53] [54] [55] . Intriguingly, CXCR4 may also be involved in cancer cell metastasis [56] [57] [58] . Monocyte chemoattractant protein-1 (MCP-1/CCL2) and CCR2 are another chemokine/receptor pair that are involved in NSC tropism for tumors [59] . Besides chemokines and their receptors, One interesting strategy involves the combination of viral-and stem cell-mediated gene therapy. Along with low transduction efficiencies, the limited spatial distribution of vectors appears to be a major reason why clinical trials of direct viral gene therapy for gliomas have been mostly unsuccessful [19, 64] . Conceivably, NSCs engineered to produce transgene-bearing viruses could deliver viral vectors directly to tumor cells. This method has the additional benefit of increasing the range of NSC-based therapy beyond secreted transgenes to include virus-delivered short-hairpin RNAs for in vivo gene knockdowns and the direct genetic manipulation of tumors [44] .
injury is one of the hallmark features of the pathophysiology of TBI leading to persistent neuromotor and cognitive deficits [68, 69] . Cognitive function is particularly affected by TBI and is believed to be attributable, in part, to selective cell death in the hippocampus [70] [71] [72] . Unfortunately, clinical trials of neuroprotective agents have thus far all failed [73] [74] [75] [76] , emphasizing the need for development of alternative therapeutic strategies.
A wide variety of cells has been tested in animal models of ischemia, TBI, and spinal cord injury [77] . Initial studies in TBI models using fetal-derived tissues or whole bone marrow [78] [79] [80] were followed by the use of immortalized neural progenitor cell lines [81] [82] [83] [84] [85] [86] [87] [88] , primary cultures of growth-factor propagated neural progenitors [89] , and more recently by studies of bone marrow stromal cells (BMSCs) [90] [91] [92] [93] [94] [95] [96] , predifferentiated mouse ES cells [97] , human umbilical cord blood (HUCB) cells [98] , and human neurospheres [99, 100] . A number of these studies have shown that transplantation of stem or progenitor cells can improve recovery following experimental TBI [77, 80, 82, 84, 85, [91] [92] [93] [94] [95] [96] [98] [99] [100] [101] [102] . In this section, we focus on regional versus systemic delivery of the cells, and the possible need for chronic delivery of neuroprotective agents.
Regulation of Gene Expression
Controlling how transgenes are expressed by NSCs is a major issue pertinent not only to the treatment of brain tumors but also to any application of stem cells as minipumps. To drive transgene expression, the most common promoters used have been either the long terminal repeat of retroviral vectors [9] or the cytomegalovirus virus (CMV) promoter [29, 43, 48, 62] . These techniques have yielded transgene levels high enough to cause measurable biological effects, but it is conceivable that finer control over the amount of expression will be required to either increase the therapeutic response or to limit toxicity. More work comparing these promoters and other genetic regulatory elements in the context of NSCs will broaden the range of transgene expression that can be achieved. Temporal regulation of transgene expression may also be beneficial in order to minimize the delivery of gene products outside of pathological areas and thus decrease the risk of side effects. One feasible approach is the use of tetracycline-responsive systems, in which transgene expression is turned on only in the presence of an appropriate antibiotic.
Challenges of a Hostile Transplantation Environment
The injured brain is an extremely challenging environment for transplantation of any cell type. TBI in rats is associated with excitotoxic damage in the initial posttraumatic period [103, 104] followed by infiltration of immune cells into the injured cortex [105] . The intense inflammatory and excitotoxic environment of the lesion prevents grafted cells from surviving in the immediate vicinity of the lesion at the time of injury, mediated in part by caspase and calpain activation in the graft [88] . Most experimental transplants are made at least 24 hours after the injury for this reason. Also, depending on the type of impact, the number of craniotomies and implantations, and the post-injury time of transplantation, the rodent brain can be significantly distorted by the impact or subsequent degeneration, shifting the standard coordinates for stereotactic transplantation.
Another relevant topic is the duration of transgene expression that can be achieved. Long-term treatment, over months and perhaps even years, will likely be necessary for the successful therapy of the diseases discussed in this review. The duration of the therapeutic effect would be governed both by the genetic regulatory elements and the lifespan of transplanted cells. Stable expression of foreign genes after in vivo transplantation of NSCs has been demonstrated in several studies [2] [3] [4] . More recent work using lentiviruses to transfer genes to endogenous NSCs has shown stable expression in vivo for up to 6-7 months in rodent models [65, 66] . Despite this data, it is likely that each transgene-stem cell combination will need to be tested individually to determine the long-term viability of transgene expression. This will be especially true in the setting of human clinical trials. Regarding the lifespan of transplanted NSCs, one potential obstacle specific to tumor therapy is NSC "suicide" secondary to the toxic effects of secreted transgene products [42] . However, it is possible to select anti-tumor agents, such as TRAIL, that would kill tumor cells but not NSCs [43, 63] .
Injury models in which a cortical cavity develops present additional challenges for transplantation experiments, due to variability in the exact location of the cavity borders from animal to animal, the severity of gliosis, and the growth of the cavity over time. Furthermore, cells transplanted into the cavity tend to disperse unless they are first embedded in a matrix. Some brain structures which are likely to respond well to neuroprotective therapy, such as the hippocampus, are easily damaged both by the injection required to place the transplant and by the physical mass of the cell bolus. Finally, the degree to which these rodent models mimic the biomechanics, pathophysiology, and other features of human brain injury continues to be hotly debated [106] [107] [108] .
TRAUMATIC BRAIN INJURY NSCs Genetically Engineered to Secrete Therapeutic Proteins
Traumatic brain injury (TBI) is a major public health problem affecting millions of people in the U.S., which can result in lifelong impairment of physical, cognitive, and psychosocial functioning [67] . Ongoing and progressive cell death (secondary or delayed damage) after the initial physical Short-term infusion of recombinant growth factors into the injured brain has been shown to be therapeutically beneficial [109] [110] [111] [112] . In contrast to cannulas, which are useful for short-term delivery but can be susceptible to infection, the use of cell transplants as biological minipumps would enable long-term delivery of the neurotrophins (weeks to months), which could potentially address the ongoing and progressive degeneration cited above. Genetically engineered cell types intended to be biological minipumps in TBI models have been engineered to constitutively overexpress and secrete either nerve growth factor (NGF) or glial cell-derived neurotrophic factor (GDNF). Preservation of endogenous cells and circuits is the goal of these experiments. For example, we tested the hypothesis that cell-based delivery of NGF to the NGFresponsive cholinergic neurons in the medial septal nucleus would preserve the septo-hippocampal pathway, a circuit that degenerates after experimental TBI and is essential for tests of cognitive function such as learning in the Morris water maze [85, 86] . The medial septum has two attractive features for transplantation experiments in TBI research. It is far from the lesion site and not directly damaged by the impact, which results in a more hospitable environment for the transplanted cells, and it undergoes cell death beginning a few days after the injury when NGF trophic support from the hippocampus is lost, which provides a potentially longer therapeutic window of opportunity.
of blood-brain barrier-permeable small molecules should be incorporated, such as tetracycline-regulated systems (reviewed in ref. [113] ). Strikingly, human neural progenitor cells survived well in transplants made immediately after an experimental brain injury [99, 100] , suggesting that some cell types may not require genetic engineering to improve their own survival in the injured brain.
Intrinsic Neuroprotective Properties of NSCs and BMSCs
Although engineered progenitor cell transplants can improve behavioral and histological outcomes in TBI models, other studies have shown that unengineered progenitor transplants may also contribute to recovery. The cell types described in this section were not genetically engineered to overexpress any neuroprotective factors, suggesting that the observed behavioral and histological improvement may be due to endogenous factors secreted from the transplants. In general, these transplanted cells exhibited limited differentiation and process outgrowth, making it unlikely that they participated in reconstructing damaged circuits.
MHP36 cells, derived from E14 hippocampal neuroepithelium and conditionally immortalized, have been extensively studied in animal models of stroke, where both histological and behavioral recovery was observed (reviewed in ref. [114] ). A preliminary report using the rat lateral fluid percussion model of brain injury showed that animals engrafted with MHP36 cells showed significantly improved learning behavior at 16 weeks post-injury when compared to brain-injured animals receiving vehicle injection, although sensorimotor function was not improved [115] . Another NSC cell line, C17.2, was derived from the external granular layer of a neonatal mouse cerebellum and transduced to express v-myc and β-galactosidase. C17.2 cells have a remarkable ability to migrate throughout the CNS during development [2] and towards areas of pathology in the adult brain [9, 116, 117] . Animals receiving C17.2 transplants either ipsilateral or contralateral to an experimental brain injury showed improved motor function but no cognitive recovery compared to injured animals transplanted with a control kidney cell line [84] . Predifferentiated mouse embryonic stem cells also improved motor but not cognitive function and significantly reduced the lesion size [97] . Finally, although they survive well in the injured brain, untransduced human NT2N neurons, which are terminally differentiated into neurons prior to transplantation, do not appear to promote histological or behavioral recovery whether they are transplanted at early (twenty-four hours) or late (one month) intervals after a brain injury [81, 83, 85, 87] .
Undifferentiated human NT2 cells were transduced with a lentiviral vector to express NGF and then differentiated into post-mitotic NT2N neurons by exposure to retinoic acid. NGF-NT2N or control NT2N neurons were transplanted into the medial septum of mice 24 hours following experimental TBI. This strategy allowed a direct comparison of the therapeutic value of a transplant that could act as a "cellular replacement" versus a transplant that additionally acts as a "biological minipump" providing trophic support. The cognitive function of the brain-injured group engrafted with NGF-NT2N neurons was significantly better than the injured group receiving vehicle or control untransduced NT2N transplants [85, 86] , showing that the trophic factor itself leads to a therapeutic benefit. In another study, HiB5 cells (derived from rat embryonic hippocampus) overexpressing nerve growth factor were transplanted into the perilesional cortex twenty-four hours after experimental TBI. One week later, neuromotor function and spatial learning were significantly improved compared to control animals receiving non-transfected cells or vehicle alone, and endogenous cell death in the CA3 region of the hippocampus was reduced [82] .
Brain-injured rats receiving transplants of GDNFexpressing C17.2 cells into the perilesional cortex at 24 hr post-injury also showed significantly improved cognitive outcome at 6 weeks post-injury as compared to animals receiving naïve C17.2 cells. The GDNF-expressing transplants also showed significantly better survival in the injured brain than control transplants did, suggesting that the neurotrophin-expressing transplants improved both host cell survival and graft cell survival, a potential additional benefit in brain injury models where graft survival is typically low [7] . Other autocrine effects of growth factor transduction should continue to be examined, as they are likely to affect other cellular processes including proliferation and differentiation. In addition, regulatory elements for the control of gene expression through the use Non-immortalized, growth-factor propagated mouse neural progenitor cells transplanted into the striatum ipsilateral to an experimental brain injury migrated extensively and improved motor function and spatial learning for as long as 1 year post-transplant [89] . This study is particularly notable for the long-term follow-up, which is relevant to understand the beneficial (or deleterious) effects of NSC transplantation on chronic behavioral disability after injury.
Although the cells described in this section were not genetically engineered to overexpress any neuroprotective factors, their role in neuroprotection is likely due to the secretion of endogenous trophic factors. For example, C17.2 cells have been shown to secrete NGF, GDNF and BDNF [118] , which may contribute to C17.2-mediated protection of MPTP-injured host nigral cells [116] , protection of host striatal cells after 3-nitropropionic acid injury [119] , and support of host axonal regeneration in the injured spinal cord [118] . neoplastic transformation. Each of these questions will require extensive laboratory efforts to answer, but the ultimate result would be a powerful new clinical tool to treat these conditions.
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Secretion of endogenous neuroprotective proteins is also postulated to underlie the histological and functional recovery observed in animals receiving intravascular infusions of unengineered bone marrow stromal cells or human umbilical cord blood cells after experimental traumatic brain injury, detailed in a series of papers by Chopp and colleagues (reviewed in ref. [120] ). Motor and neurological deficits were reduced within 2 weeks of infusion of BMSCs into the tail vein of brain-injured rats [91, 96] or 4 weeks after infusion of HUCB cells [98] . Notably, brain concentrations of NGF and BDNF were elevated in the BMSC-treated groups. The BMSCs expressed both growth factors and may have also induced their expression in host glial cells [94] . The fact that intravenous delivery of BMSCs leads to engraftment in many organs may preclude their genetic engineering to overexpress a neurotrophin, given the potential adverse effects of systemic neurotrophin administration [121, 122] .
Other intriguing findings from these papers include the preferential migration of infused BMSCs into injured brain [90, 91, 93, 94, 96, 98, 123] and an apparent increase in proliferation in endogenous neurogenic zones and at the injury boundary in animals that received either intracranial or intravascular BMSCs [93] , The use of bone-marrow derived cells clearly has important clinical implications. Bonemarrow cells are potentially much easier to harvest, can be autologous or matched to the patient more readily, and can be delivered intravascularly, altogether avoiding neurosurgical intervention and transplantation of a cell mass into an already damaged brain.
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